<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487706</url>
  </required_header>
  <id_info>
    <org_study_id>DTG_HD</org_study_id>
    <nct_id>NCT02487706</nct_id>
  </id_info>
  <brief_title>Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease</brief_title>
  <official_title>Removal of Dolutegravir by Hemodialysis in HIV-infected Patients With End-stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundaci贸n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoci贸n de la Salud y la Ciencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundaci贸n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoci贸n de la Salud y la Ciencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data on the capacity of hemodialysis to remove dolutegravir (DTG) from plasma in patients&#xD;
      with end-stage renal disease (ESRD) on hemodialysis (HD) are lacking. If DTG was removed from&#xD;
      plasma by HD, it would be possible to have subtherapeutic drug concentrations at the end of&#xD;
      HD sessions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of chronic renal disease and end-stage renal disease (ESRD) is increasing in&#xD;
      the HIV-positive population. This means that an increasing number of HIV-infected patients&#xD;
      will need renal replacement therapy.However, little is known about DTG removal from plasma by&#xD;
      HD in patients with ESRD.&#xD;
&#xD;
      Objective: to evaluate the effect of HD on DTG clearance as well as on DTG plasma&#xD;
      concentrations at steady state in HIV-infected patients with ESRD undergoing HD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemodialysis extraction ratio of dolutegravir</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hemodialysis clearance of dolutegravir</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients presenting adverse events related to dolutegravir</measure>
    <time_frame>From Baseline to day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Dolutegravir 50mg/day per 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg/day per 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>Dolutegravir 50mg/day per 5 days</description>
    <arm_group_label>Dolutegravir 50mg/day per 5 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age 1 years old or older.&#xD;
&#xD;
          2. HIV documented infection (western blot)&#xD;
&#xD;
          3. ESRD undergoing routine hemodialysis&#xD;
&#xD;
          4. Stable antiretroviral treatment (no changes within the prior 2 weeks)&#xD;
&#xD;
          5. Signature of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inadequate adherence to antiretroviral treatment (&lt;90% in the week prior to&#xD;
             inclusion).&#xD;
&#xD;
          2. Clinical evidence or suspicion that the patient will not be able to comply with the&#xD;
             study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>HIV-infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

